J0651 Levothyroxine (HCPCS) Reimbursement

HCPCS Level II code J0651 represents a 10 mcg injection of levothyroxine sodium (Fresenius Kabi), designated as not therapeutically equivalent to J0650. This code identifies a specific injectable formulation of thyroid hormone used in clinical settings where parenteral administration is required. Nationally, accurate coding of injectable levothyroxine supports appropriate claims processing, product-specific tracking, and clinical documentation for patients requiring non-oral thyroid hormone delivery.

Key payers in the scope of this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and the types of benchmarks and policy elements commonly reviewed for HCPCS drug codes: coverage determinations, billing and administration guidance, and payer-specific billing considerations. The publication outlines which payers are included in comparisons and highlights where data is unavailable.

This summary equips billing staff, revenue cycle managers, and policy analysts with the essential facts about J0651, what to expect in payer coverage reviews, and which areas require checking payer-specific policies or formularies. Data not available in the input will be noted where relevant in detailed sections.

Billing Code Overview

HCPCS Level II code J0651 describes an injection of levothyroxine sodium (Fresenius Kabi), 10 mcg, noted as not therapeutically equivalent to J0650. The service type is therapeutic injectable medication administration intended to deliver a specific thyroid hormone dose. The typical site of service is outpatient infusion/injection settings or facility-based administeration (e.g., hospital outpatient department, clinic, or infusion center).

Data not available in the input.

Clinical Context

A 62-year-old female with previously diagnosed hypothyroidism who is unable to tolerate or absorb oral levothyroxine presents to an outpatient infusion center for parenteral thyroid hormone replacement. She has a history of gastric bypass surgery and chronic malabsorption with persistent hypothyroid symptoms despite high-dose oral therapy. The ordering clinician documents persistent fatigue, weight gain, and elevated TSH despite adherence. The patient receives an intramuscular or subcutaneous injection of J0651 (levothyroxine sodium, 10 mcg) prepared and administered by a licensed clinician in a clinic or infusion suite.

The clinical workflow includes: verification of the medication order and dose, review of allergies and consent, preparation of the unit-dose product, site selection and aseptic technique for injection, administration of the injection, monitoring for immediate adverse reaction, and documentation of lot number, amount administered, route, site, and patient response in the medical record. Follow-up includes scheduled TSH and free T4 testing and documentation of subsequent dose adjustments.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered	Use when part of the single-use vial is discarded after partial administration per facility policy.

Taxonomy Code	Specialty	Notes
`207P00000X`	Endocrinology	Specialists who manage hypothyroidism and may order parenteral levothyroxine when oral therapy is not feasible.
`163W00000X`	Internal Medicine	Hospitalists and outpatient internists who treat chronic thyroid disease and manage medication changes.
`363A00000X`	Nurse Practitioner	Advanced practice clinicians who may order, administer, or coordinate parenteral therapy in clinic settings.
`207L00000X`	Family Medicine	Primary care clinicians managing long-term hypothyroid care and coordinating specialty referrals.
`165H00000X`	Physician Assistant	PAs working in endocrinology or primary care clinics involved in medication management.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E03.9`	Hypothyroidism, unspecified	Primary indication for levothyroxine replacement when oral therapy is inappropriate or ineffective.
`E03.8`	Other specified hypothyroidism	Used for secondary forms or specific subtypes of hypothyroidism requiring alternative administration.
`E03.3`	Postinfectious hypothyroidism	Relevant when thyroid dysfunction follows infection and parenteral therapy is needed temporarily.
`E89.0`	Postprocedural hypothyroidism	Relevant when thyroid surgery or radioiodine leads to hypothyroidism requiring replacement.
`K90.0`	Celiac disease	Example of malabsorption disorder that can impair oral levothyroxine absorption, prompting parenteral use.
`Z90.490`	Acquired absence of both ovaries and testes (used illustratively for postsurgical states)	Included as a potential postsurgical status that may affect endocrine management (use only when clinically applicable).
`Z79.899`	Other long term (current) drug therapy	Indicates ongoing need for chronic medication therapy including thyroid hormone replacement.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Used to report the administration service when `J0651` is given via IM or SC injection in an outpatient setting.
`36415`	Collection of venous blood by venipuncture	Performed before or after injection for TSH and free T4 monitoring and drug level assessment.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	Common for the follow-up visit documenting treatment rationale, response, and ordering labs after parenteral levothyroxine.
`99070`	Supplies and materials (except spectacles), provided by physician over and above those usually included with the office visit	May be used to report ancillary supplies associated with injection preparation if payer allows.
`96361`	Hydration, IV, for infusion therapy supervision and management, initial 31 minutes to 1 hour	Rarely applicable; included only if the patient requires monitored infusion services related to treatment (typically not for single-dose injection).

OpenPayer

Summary & Overview

HCPCS J0651: Levothyroxine Sodium Injection, 10 mcg